“Drug Watch” Sent Back To The Drawing Board; FDA Turning To MedWatch?
Executive Summary
FDA is considering proactive communication of early adverse event reports from its MedWatch monitoring system as the agency reassesses its proposed Drug Watch website for emerging safety information
You may also be interested in...
FDA, MIT Collaborate On Development Of Active Drug Safety Surveillance Tool
FDA is working with the Massachusetts Institute of Technology's Center for Biomedical Innovation to develop an active drug safety surveillance system
FDA, MIT Collaborate On Development Of Active Drug Safety Surveillance Tool
FDA is working with the Massachusetts Institute of Technology's Center for Biomedical Innovation to develop an active drug safety surveillance system
Boxed Warnings, Drug Watch Are Policy Goals Of Drug Safety Oversight Board
FDA's Drug Safety Oversight Board should start shifting its focus toward broader policy questions - like standards for boxed warnings - in addition to addressing emerging safety issues for specific products, DSOB Executive Director Susan Cummins suggested